Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Stephen D. Wilson who wrote (721)	5/5/1998 7:59:00 AM
From: Omer Shvili	Read Replies (1) \| Respond to of 1491

PARS will probably release results for the first two groups sometime this summer - I guess August is a safe bet. They do a follow-up of several months on each patient that is enrolled, and by this summer they'll finish this follow-up with all the patients in the first two groups. The results for the third group (highest dosage) will be out late this year or by early '99. BTW, the third dosage isn't done in order to see if there are side-affects or any other problems, they want to see if it gets better results. PARS already did a study in which they found at what level HU211 is neurotoxic. Let's cross our fingers for good results. Like Mr. Fernandez said, even a 50% improvement is good, and I believe we'll see even better results. Omer